# A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

> **NCT04090658** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04090658
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-25
- **Primary completion:** 2020-01-10
- **Final completion:** 2020-12-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090658, "A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04090658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*